CNS Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Rhea-AI Summary

CNS Pharmaceuticals (NASDAQ: CNSP) announced that CEO John Climaco will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020, at 10:00 AM EDT. The company is focused on developing treatments for central nervous system cancers, with its lead candidate, Berubicin, showing promising results in a completed Phase 1 trial for glioblastoma multiforme. A replay of the presentation will be available on the company’s website for 90 days following the event.

HOUSTON, Sept. 17, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today announced that CEO, John Climaco, will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Tuesday, September 22^nd, 2020 at 10:00 AM EDT.

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date:	Tuesday, September 22nd, 2020
Time:	10:00 AM EDT
Link:	http://wsw.com/webcast/oppenheimer5/cnsp/2726100

A replay of the presentation will be available on the Company's website for 90 days following the event. Members of management will hold 1-on-1 virtual investor meetings at the conference. Investors attending the conference virtually who are interested in meeting with Company management should contact their Oppenheimer representatives.

About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006.  In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland.  Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation.

View original content to download multimedia:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-present-at-the-oppenheimer-fall-healthcare-life-sciences--medtech-summit-301132810.html

SOURCE CNS Pharmaceuticals, Inc.

FAQ

What date and time is CNS Pharmaceuticals presenting at the Oppenheimer Summit?

CNS Pharmaceuticals is presenting on September 22, 2020, at 10:00 AM EDT.

Who is the CEO of CNS Pharmaceuticals?

The CEO of CNS Pharmaceuticals is John Climaco.

What is the lead drug candidate of CNS Pharmaceuticals?

The lead drug candidate is Berubicin, aimed at treating glioblastoma multiforme.

Where can I watch the CNS Pharmaceuticals presentation?

You can watch the presentation at the Oppenheimer Summit via the link provided, and a replay will be available on the company's website for 90 days.

What were the results of the Phase 1 trial for Berubicin?

In the Phase 1 trial, 44% of patients experienced a statistically significant improvement in clinical benefit.